Drug Trial Radar · NCT04180371
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
288
Planned (sponsor's estimate)
Start
Nov 7, 2019
Primary completion
Dec 31, 2026
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- BicycleTx LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: * Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab * Learn more about the side effects of BT5528 * Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer. * Learn more about BT5528 therapy alone and in combination with nivolumab.
Conditions
- Advanced Solid Tumor Historically Known for High EphA2 Expression
- Urothelial Cancer
- Ovarian Cancer
- Non-small Cell Lung Cancer
- Head and Neck Cancer
- Triple Negative Breast Cancer
- Gastric/Upper Gastrointestinal Cancer
Interventions
BT5528Drug
Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.
NivolumabDrug
Participants will receive nivolumab at 480mg intravenous infusion every 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A-1 and A-2(escalations): Number of participants receiving BT5528 alone and in combination with nivolumab with treatment-emergent adverse eventsTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until 30 days post last dose
- Part A-1 and A-2 (escalations): Maximum tolerated dose (MTD) by the number of participants with dose limiting toxicities from BT5528 treatment alone and in combination with nivolumabTime frame: At the end of Cycle 1 (each cycle is 28 days)
- Part B: Objective response rate by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 tumor expression receiving BT5528 treatmentTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment)
- Part B: Duration of response by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 receiving BT5528 treatmentTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment)
- Part B: Clinical benefit rate by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 receiving BT5528 treatmentTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment)
- Part B: Time to tumor progression by RECIST 1.1 in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatmentTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment)
- Part B: Progression-free survival by RECIST 1.1 in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatmentTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment)
- Part B: PFS at 6 months by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 receiving BT5528 treatmentTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks up to 6 months)
- Part B: Overall survival (OS) at 1 year in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatmentTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until death or loss of follow-up or withdrawal of consent
Locations
28 sites in 5 countries. Site status is shown where the registry gives one.
California Cancer Associates for Research and Excellence, Inc.
Encinitas, California
University of California - Irvine Medical Center
Orange, California
Sarah Cannon Research Institute at HealthONE
Denver, Colorado
Florida Cancer Specialists
Sarasota, Florida
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York
Stephenson Cancer Center (Oklahoma University)
Oklahoma City, Oklahoma
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania
Sarah Cannon and HCA Research Institute
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Institut Jules Bordet
Brussels, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Antwerp University Hospital (UZA)
Edegem, Belgium
Universitair Ziekenhuis Gent (UZ)
Ghent, Belgium
Gachon University Gil Medical Center
Incheon, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Institut Catala d'Oncologia - L'Hospitalet
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Fundación Jimenez Diaz
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Centro Integral Oncologico Clara Campal
Madrid, Spain
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
The Leeds Teaching Hospitals NHS Trust Of Trust Headquarters, St James's University Hospital
Leeds, United Kingdom
Sir Bobby Robson Cancer Trials Research Centre, The Northern Center for Cancer Care, Freeman Hospital
Newcastle upon Tyne, United Kingdom
Sarah Cannon Research Institute UK
London, United Kingdom, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.